← Sulfonylureas & glinides × adverse events & safety

Observational studyJAMA network open2018

Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin: Analysis From the Observational Health Data Sciences and Informatics Initiative.

Rohit Vashisht et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 805 people · 2018

Range includes no effect

No clear effect on adverse events & safety

−1%−11% to +10%

Smaller than almost all for adverse events & safety

As reported

HR 0.99, 95% CI 0.89–1.10

What moved togetherboth groups pooled, not the treatment’s effect

Correlation, not cause

Went with more cardiovascular events

+12%+2% to +24%

Bigger than 2 in 10 for cardiovascular events

As reported

HR 1.12, 95% CI 1.02–1.24

Two numbers in the abstract

the abstract, start to end

… of myocardial infarction (consensus HR, 1.12; 95% CI, 1.02-1.24) and eye …

… total hemoglobin or less (consensus HR, 0.99; 95% CI, 0.89-1.10) ( Table 2 …

← favours treatmentfavours comparator →
could be chance
Cardiovascular events
HR 1.121.02–1.24
Adverse events & safety
HR 0.990.89–1.10
Sulfonylureas & glinidesCardiovascular eventsAdverse events & safety
1 / 4

35 papers cite it

2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled itcites it
Full record →Abstract, authors, funding and every citing paper · PMID 30646124